Vyloy
Total Payments
$352,877
Transactions
1,578
Doctors
1,218
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $352,877 | 1,578 | 1,218 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $141,203 | 69 | 40.0% |
| Consulting Fee | $96,724 | 33 | 27.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,113 | 19 | 15.3% |
| Food and Beverage | $38,482 | 1,397 | 10.9% |
| Travel and Lodging | $22,357 | 60 | 6.3% |
Payments by Type
General
$211,674
1,509 transactions
Research
$141,203
69 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | Astellas Pharma Global Development | $87,112 | 0 |
| A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Astellas Pharma Global Development | $49,603 | 0 |
| A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination With mFOLFOX6 in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Whose Tumors Have High or Intermediate Claudin (CLDN) 18.2 Expression | Astellas Pharma Global Development | $2,488 | 0 |
| A Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination With Chemotherapy (mFOLFIRINOX) in Participants With CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma | Astellas Pharma Global Development | $2,000 | 0 |
Top Doctors Receiving Payments for Vyloy — Page 9
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , FAMILY NP | Family | West Islip, NY | $34.55 | 1 |
| , PA-C | Medical | Meyersdale, PA | $34.23 | 1 |
| , NPC | Family | Cumberland, MD | $34.23 | 1 |
| , CNP | Nurse Practitioner | Columbus, OH | $33.88 | 1 |
| , M.D | Hematology & Oncology | Westerville, OH | $33.88 | 1 |
| , MD | Hematology & Oncology | Columbus, OH | $33.88 | 1 |
| , PA | Physician Assistant | Columbus, OH | $33.88 | 1 |
| , MD | Internal Medicine | Golden, CO | $33.83 | 1 |
| , M.D | Medical Oncology | Parker, CO | $33.83 | 1 |
| , NP, RN | Nurse Practitioner | Denver, CO | $33.83 | 1 |
| , M.D | Hematology & Oncology | Denver, CO | $33.83 | 1 |
| , CNS | Nurse Practitioner | Denver, CO | $33.83 | 1 |
| , NP-C | Nurse Practitioner | Parker, CO | $33.82 | 1 |
| , M.D | Hematology & Oncology | Fresno, CA | $33.73 | 2 |
| , M.D | Hematology & Oncology | West Hills, CA | $33.50 | 1 |
| , NP-C, MSN, RN, OCN | Nurse Practitioner | New Milford, NJ | $33.46 | 2 |
| , MD | Hematology & Oncology | Mission Hills, CA | $33.45 | 1 |
| , MD | Medical Oncology | North Bergen, NJ | $33.44 | 2 |
| , M.D | Internal Medicine | Fort Myers, FL | $33.41 | 2 |
| , M.D | Hematology & Oncology | Pleasant Hill, CA | $33.36 | 1 |
| , M.D | Hematology & Oncology | Saint Helena, CA | $33.36 | 1 |
| , MD | Radiation Oncology | Walnut Creek, CA | $33.35 | 1 |
| , FNP | Family | Rocky Point, NY | $33.25 | 1 |
| , MD | Hospitalist | Corvallis, OR | $33.03 | 1 |
| , MD | Internal Medicine | Philadelphia, PA | $32.90 | 1 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $197,885
- Astellas Pharma US Inc $154,992
Product Information
- Type Drug
- Total Payments $352,877
- Total Doctors 1,218
- Transactions 1,578
About Vyloy
Vyloy is a drug associated with $352,877 in payments to 1,218 healthcare providers, recorded across 1,578 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2024 to 2024. In 2024, $352,877 was paid across 1,578 transactions to 1,218 doctors.
The most common payment nature for Vyloy is "Unspecified" ($141,203, 40.0% of total).
Vyloy is associated with 4 research studies, including "A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma" ($87,112).